SynAct Pharma Board and Management extend lock-up period   UK Version

Report this content

SynAct Pharma AB ("SynAct") today announced all members of its board and management team have extended the lock-up period for their SynAct Pharma shares until December 31, 2021. In total the lock-up agreements correspond to more than 20 percent of the votes and capital in SynAct Pharma.

“The members of the board and the entire management team have no intention of selling their shares now,” said Jeppe Øvlesen, CEO of SynAct Pharma. “We all see the incredible long-term potential our pipeline has and are committed to helping this company reach its potential.”

The information was submitted, through the agency of the contact person below, for publication on Mai 4, 2021.

For further information about SynAct Pharma AB, please contact:

Jeppe Øvlesen                                                                                Thomas Jonassen

CEO, SynAct Pharma AB                                                                CSO, SynAct Pharma AB

Phone: +45 28 44 75 67                                                                  Phone: +45 40 15 66 69

Mail:                                                         Mail:

About SynAct Pharma AB

SynAct Pharma AB conducts research and development in inflammatory diseases. The company has a platform technology based on a new class of drug candidates aimed at acute deterioration in chronic inflammatory diseases with the primary purpose of stimulating natural healing mechanisms. For more information: